---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-005421"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2026-05-18T21:00:15+00:00"
generated_at: "2026-05-18T21:09:07.160252+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeOnc reports Q1 net loss $8.8M; NEO212 Phase 1 complete, NEO100 interim data Aug 2026

## Summary
- Net loss $8.8M ($0.38/diluted) vs $32.3M ($1.78) in Q1 2025; G&A down to $489K, R&D up to $1.29M.
- Cash $138,601 at Mar 31; $10M PIPE from Cinctive Capital and $10M undrawn credit line fund ops into Sep 2026.
- NEO212 Phase 1 complete, RP2D set at 610 mg; FDA End-of-Phase 1 meeting planned for potential registrational Phase 2.
- NEO100 Phase 2a fully enrolled in IDH1-mutant high-grade glioma; interim data readout expected August 2026.
- Appointed David Choi as CAO; CEO Amir Heshmatpour purchased >$500k of NTHI shares in open market.

## SEC filing metadata
- accession: 0001829126-26-005421
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2026-05-18T21:00:15+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912626005421/0001829126-26-005421-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912626005421/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-005421
- JSON: https://secwatch.observer/filing/0001829126-26-005421.json
- Plain text: https://secwatch.observer/filing/0001829126-26-005421.txt

## Key facts
- Earnings Releases
  NEONC TECHNOLOGIES HOLDINGS, INC. reported first quarter ended March 31, 2026 results: net income $8.8 million or $(0.38) per diluted share, EPS $(0.38) per diluted share.
  - Period: first quarter ended March 31, 2026
  - Net income: $8.8 million or $(0.38) per diluted share
  - EPS: $(0.38) per diluted share
  - Result: reported results
  source text: NeOnc Provides Business Update and Reports Q1 2026 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1979414/000182912626005421/0001829126-26-005421-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.